GADL1

Across TCGA pan-cancer cohorts, GADL1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated GADL1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher GADL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GADL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

SCLC, BLCA, and UCEC are the cancer types where GADL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.146	0.638	<.001	27	view →
BLCA	OS	Median	All	0.174	0.720	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.014	18	view →
COAD	DFS	Median	II,III,IV	0.220	0.779	.001	17	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
PAAD	DFS	Median	All	0.060	0.484	<.001	12	view →
CESC	OS	Median	All	0.095	0.585	.038	6	view →
SARC	OS	Median	All	0.143	0.745	<.001	6	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUAD	OS	Median	All	1.000	0.677	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

GADL1–SCLC (DFS)

Open the SCLC breakdown →